Gilad W. Vainer

1.1k total citations
28 papers, 700 citations indexed

About

Gilad W. Vainer is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Gilad W. Vainer has authored 28 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Gilad W. Vainer's work include Cancer Immunotherapy and Biomarkers (6 papers), Genetic factors in colorectal cancer (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Gilad W. Vainer is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Genetic factors in colorectal cancer (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Gilad W. Vainer collaborates with scholars based in Israel, United States and Germany. Gilad W. Vainer's co-authors include Eli Pikarsky, Yinon Ben‐Neriah, Tzahi Neuman, Felix Bokstein, Alexander Lossos, Hanita Khaner, Yaniv Zohar, Maria Idelson, Christian Rolfo and Ludmila Fridel and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Oncogene.

In The Last Decade

Gilad W. Vainer

25 papers receiving 692 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gilad W. Vainer Israel 14 297 257 245 213 82 28 700
Nadia Coltella Italy 16 387 1.3× 194 0.8× 206 0.8× 114 0.5× 68 0.8× 24 709
Heather M. Shaw United Kingdom 13 349 1.2× 352 1.4× 116 0.5× 132 0.6× 55 0.7× 34 725
Fernando Pardal Portugal 16 404 1.4× 236 0.9× 211 0.9× 123 0.6× 212 2.6× 26 829
Ana Teresa Amaral Spain 13 317 1.1× 206 0.8× 150 0.6× 244 1.1× 32 0.4× 20 633
Munehiro Kishi Japan 15 450 1.5× 240 0.9× 159 0.6× 128 0.6× 66 0.8× 17 709
Joana Vieira Portugal 14 344 1.2× 220 0.9× 134 0.5× 293 1.4× 42 0.5× 39 701
Yvonne Parker United States 13 378 1.3× 194 0.8× 223 0.9× 142 0.7× 63 0.8× 24 734
Antonios Papanicolau‐Sengos United States 12 237 0.8× 275 1.1× 165 0.7× 149 0.7× 31 0.4× 36 563
Linni Fan China 16 319 1.1× 151 0.6× 186 0.8× 93 0.4× 34 0.4× 50 649

Countries citing papers authored by Gilad W. Vainer

Since Specialization
Citations

This map shows the geographic impact of Gilad W. Vainer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilad W. Vainer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilad W. Vainer more than expected).

Fields of papers citing papers by Gilad W. Vainer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilad W. Vainer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilad W. Vainer. The network helps show where Gilad W. Vainer may publish in the future.

Co-authorship network of co-authors of Gilad W. Vainer

This figure shows the co-authorship network connecting the top 25 collaborators of Gilad W. Vainer. A scholar is included among the top collaborators of Gilad W. Vainer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilad W. Vainer. Gilad W. Vainer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oberman, Froma, Myriam Grunewald, Amandeep Singh, et al.. (2025). AVJ16 inhibits lung carcinoma by targeting IGF2BP1. Oncogene. 44(35). 3239–3254.
2.
Vainer, Gilad W., Sunil Badve, Fernando Augusto Soares, et al.. (2025). Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications. Frontiers in Oncology. 15. 1581275–1581275.
3.
Oberman, Froma, Yuval Cinnamon, Mordechai Golomb, et al.. (2023). RNA binding protein IGF2BP2 expression is induced by stress in the heart and mediates dilated cardiomyopathy. Communications Biology. 6(1). 1229–1229. 8 indexed citations
4.
Heitzer, Ellen, Daan van den Broek, Marc G. Denis, et al.. (2022). Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. ESMO Open. 7(2). 100399–100399. 74 indexed citations
5.
Hirshoren, Nir, Jeffrey M. Weinberger, Ron Eliashar, et al.. (2021). Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma. Oncology. 99(7). 464–470. 20 indexed citations
6.
Levin, Yishai, et al.. (2020). Novel Proteome Extraction Method Illustrates a Conserved Immunological Signature of MSI-H Colorectal Tumors. Molecular & Cellular Proteomics. 19(10). 1619–1631. 1 indexed citations
7.
Hertz, Rachel, et al.. (2020). Treatment of ErbB2 breast cancer by mitochondrial targeting. SHILAP Revista de lepidopterología. 8(1). 17–17. 7 indexed citations
8.
Zigmond, Ehud, Keren Merenbakh-Lamin, Metsada Pasmanik‐Chor, et al.. (2018). Klotho suppresses colorectal cancer through modulation of the unfolded protein response. Oncogene. 38(6). 794–807. 41 indexed citations
9.
Menes, Tehillah S., Gilad W. Vainer, Hedva Lerman, et al.. (2016). Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes. Clinical Breast Cancer. 16(5). 389–395. 8 indexed citations
10.
Neuman, Tzahi, et al.. (2016). A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana’s Platform. Journal of Thoracic Oncology. 11(11). 1863–1868. 70 indexed citations
11.
Blumenthal, Deborah T., Michal Yalon, Gilad W. Vainer, et al.. (2016). Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. Journal of Neuro-Oncology. 129(3). 453–460. 76 indexed citations
12.
Vainer, Gilad W., et al.. (2014). PF-4708671 Activates AMPK Independently of p70S6K1 Inhibition. PLoS ONE. 9(9). e107364–e107364. 8 indexed citations
13.
Ergaz, Zivanit, et al.. (2014). Congenital fulminant Kaposiform hemangioendothelioma of the leg. Reproductive Toxicology. 50. 1–3.
14.
Nechushtan, Hovav, et al.. (2014). A phase 1/2 of a combination of Cetuximab and Taxane for “triple negative” breast cancer patients. The Breast. 23(4). 435–438. 20 indexed citations
15.
Shofty, Ben, Shlomi Constantini, Felix Bokstein, et al.. (2013). Optic Pathway Gliomas in Adults. Neurosurgery. 74(3). 273–280. 15 indexed citations
16.
Sonnenblick, Amir, Yakir Rottenberg, Luna Kadouri, et al.. (2012). Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer. Medical Oncology. 29(5). 3035–3038. 4 indexed citations
17.
Gropp, Michal, Vitali Shilo, Gilad W. Vainer, et al.. (2012). Standardization of the Teratoma Assay for Analysis of Pluripotency of Human ES Cells and Biosafety of Their Differentiated Progeny. PLoS ONE. 7(9). e45532–e45532. 92 indexed citations
18.
Vainer, Gilad W., Eli Pikarsky, & Yinon Ben‐Neriah. (2008). Contradictory functions of NF-κB in liver physiology and cancer. Cancer Letters. 267(2). 182–188. 55 indexed citations
19.
Vainer, Gilad W., Alon J. Pikarsky, Shailesh M. Shenoy, et al.. (2008). A role for VICKZ proteins in the progression of colorectal carcinomas: regulating lamellipodia formation. The Journal of Pathology. 215(4). 445–456. 35 indexed citations
20.
Natkunam, Yasodha, Gilad W. Vainer, Jun Chen, et al.. (2007). Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms. Haematologica. 92(2). 176–183. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nadia Coltella Breakdown of academic impact, for papers by Heather M. Shaw Breakdown of academic impact, for papers by Fernando Pardal Breakdown of academic impact, for papers by Ana Teresa Amaral Breakdown of academic impact, for papers by Munehiro Kishi Breakdown of academic impact, for papers by Joana Vieira Breakdown of academic impact, for papers by Yvonne Parker Breakdown of academic impact, for papers by Antonios Papanicolau‐Sengos Breakdown of academic impact, for papers by Linni Fan
Rankless by CCL
2026